Exponential Health, an innovative concierge healthcare provider in Michigan, adopts Cardio Diagnostics' AI-powered epigenetic genetic testing to usher in a new era of personalized, preventative cardiac care.
Chicago, April 9, 2024–(BUSINESS WIRE)–In a major step toward transforming cardiovascular care in concierge specialty and primary care offices, Exponential Health, an innovative concierge healthcare organization led by Dr. William Baer, is pleased to announce Cardio We plan to provide services to Diagnostics Holdings, Inc. s (Nasdaq: CDIO) provides clinical epigenetic-genetic cardiovascular testing, Epi+Gen CHD and PrecisionCHD, to patients. As a result, Exponential Health is expanding access to a new chapter in the preventive management of heart disease.
Exponential Health emphasizes a more personalized, patient-centered approach to preventive care. Its value-based care model allows Exponential Health to spend more time with each patient, conduct comprehensive assessments, and create personalized preventive care plans for patients.
Synergy of innovation and expertise in precision care
The US concierge pharmaceutical market size is estimated to be USD 6.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 10.37% from 2024 to 2030 to reach USD 13.3 billion. This growth is being driven by increasing demand for convenient care, the benefits that concierge medicine brings to patients, and increasing career satisfaction for concierge physicians.
Concierge practices such as Exponential Health are leading the way in implementing epigenetic cardiovascular solutions. This partnership sets a new benchmark for concierge practices that combine advanced medical technology with unparalleled personalized clinical expertise to enhance preventive cardiology in primary care. Exponential Health uses Cardio Diagnostics' solutions to proactively identify and monitor patients for early assessment, diagnosis, and diagnosis of coronary heart disease, the most common type of heart disease and the leading cause of heart attacks. We aim to intervene with an innovative framework for management. The clinic offers patients a more personalized healthcare journey.
“Our partnership with Cardio Diagnostics is a testament to our dedication to embracing innovative solutions that enhance patient care,” said Dr. William Baer, founder of Exponential Health. , we will be able to detect and respond,” he said, expressing enthusiasm about the partnership. This aligns perfectly with our mission to provide excellent personalized care. ”
Cardio Diagnostics' cutting-edge tests, Epi+Gen CHD and PrecisionCHD, combine genomics, epigenomics, and artificial intelligence to assess risk of coronary heart disease events and aid in the diagnosis of coronary heart disease, respectively. It is designed to. Combining these tests with Cardio Diagnostics' Actionable Clinical Intelligence platform provides critical insight into a patient's cardiovascular health at the molecular level, enabling earlier intervention and customized treatment strategies with greater precision. Become.
Transforming cardiovascular health management
Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics, said: “This partnership is a powerful demonstration of our shared commitment to advancing cardiovascular health through innovation. By integrating our precision medicine solutions into Exponential Health practices, we will is poised to make a major impact in preventing cancer and improving patient outcomes.”
This collaboration comes at a pivotal moment, as cardiovascular disease remains the leading cause of death worldwide. Integrating Cardio Diagnostics' advanced testing into Exponential Health's products is a positive step toward mitigating this global health challenge. This provides patients with access to state-of-the-art diagnostic tools that facilitate informed decision-making and personalized prevention plans.
About heart diagnosis
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and accurate. The Company is a leading medical technology company that leverages its unique artificial intelligence (AI)-driven integrated gene-epigenetic engine for cardiovascular diseases (the “Core Technology”) to further develop and commercialize clinical tests to improve prevention and detection. It was established to become one of the companies. , treatment of cardiovascular diseases. For more information, please visit www.cardiodiagnosticsinc.com.
About Exponential Health
Exponential Health is a leading concierge healthcare organization that prioritizes preventive medicine and early detection to optimize health and wellness. Founded by Dr. William Baer, a pioneer in preventive and personalized medicine, Exponential Health leverages cutting-edge technology and personalized care to revolutionize the healthcare experience and help patients achieve their best health outcomes. We will support you to do so.
Forward-looking statements
Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words and phrases “will,” “likely to result,” and “anticipated” are used. “…”, “continue”, “anticipate”, “estimate”, “anticipate”, “intend”, “goal” or similar expressions mean “future” within the meaning of Private Securities Litigation Reform. The objective is to identify “forward-looking statements”. 1995 Act. Such statements are subject to certain known and unknown risks and uncertainties, many of which are beyond the Company's control. Such uncertainties and risks include our ability to successfully execute our growth strategy, changes in laws and regulations, economic conditions, dependence on management, shareholder dilution, capital shortfalls and rapid growth. including, but not limited to, the impact on our company and other factors. Financing our management's ability to effectively respond to growth and demand on our products and services, newly developed technologies, our ability to compete, regulatory matters, technology protection, the effects of competition and our future acquired capabilities; An extensive list of factors that may affect future results is included in our Form 10-K for the periods ended December 31, 2022, and March 31, 2023 and September 30, 2023. Current Report on Form 10-Q for the period discussed. Part I, Item IA under the heading “Risk Factors” and other documents filed from time to time with the Securities and Exchange Commission. Such factors could have a material adverse effect on our financial results and could cause our actual results in future periods to differ materially from the opinions and statements expressed in this press release. There is a gender.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240409605762/ja/
contact address
Investor:
Gene Mannheimer
PR for investors
855-226-9991
investors@cardiodiagnosticsinc.com
Media and public relations:
Quran Abdullahi
855-226-9991
pr@cardiodiagnosticsinc.com
